Patients' Characteristics Affect the Survival Benefit of Warfarin Treatment for Hemodialysis Patients with Atrial Fibrillation. A Historical Cohort Study | Zendy

Diego Brancaccio | Zendy; Luca Neri | Zendy; Francesco Bellocchio | Zendy; C. Barbieri | Zendy; Claudia Amato | Zendy; Flavio Mari | Zendy; Bernard Canaud | Zendy; Stefano Stuard | Zendy

Open Access

Patients' Characteristics Affect the Survival Benefit of Warfarin Treatment for Hemodialysis Patients with Atrial Fibrillation. A Historical Cohort Study

Author(s) -

Diego Brancaccio,

Luca Neri,

Francesco Bellocchio,

C. Barbieri,

Claudia Amato,

Flavio Mari,

Bernard Canaud,

Stefano Stuard

Publication year - 2016

Publication title -

american journal of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.394

H-Index - 85

eISSN - 1421-9670

pISSN - 0250-8095

DOI - 10.1159/000448898

Subject(s) - medicine , warfarin , atrial fibrillation , hazard ratio , stroke (engine) , dialysis , hemodialysis , population , cohort , proportional hazards model , randomized controlled trial , vitamin k antagonist , propensity score matching , intensive care medicine , confidence interval , mechanical engineering , environmental health , engineering

Stroke prevention in dialysis-dependent patients with atrial fibrillation (AF) is an unresolved clinical dilemma. Indeed, no randomized controlled trial evaluating the efficacy and safety of oral anticoagulants in this population, has been conducted so far. Observational research on the use of warfarin in patients on dialysis has shown conflicting results. This uncertainty is mirrored by the wide variations in warfarin prescription patterns across centers. We sought to evaluate the association between the use of vitamin K antagonists (VKAs) and mortality among hemodialysis patient with AF and to assess potential factors affecting the risk-benefit profile of warfarin in this population.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research